A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

Trial Profile

A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Duvelisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; MALT lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Acronyms DYNAMO
  • Sponsors Infinity Pharmaceuticals; Verastem
  • Most Recent Events

    • 08 Aug 2017 According to a Verastem media release, results from this trial have been presented at the 14th International Conference on Malignant Lymphoma (ICML).
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Results from a double refractory iNHL population, which included 28 patients (pts) with small lymphocytic lymphoma (SLL), presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top